iBio Seeks Approval to Double Authorized Shares to 500M and Expand Equity Plan
IBIO sits 70% above its 52-week low of $0.771 on light trading volume (0.3× avg).
Summary
iBio's definitive proxy seeks shareholder approval to double authorized shares to 500 million and adjust its equity plan to account for 93.4 million outstanding pre-funded warrants, while also disclosing FY2027 executive salary increases.
Key Events · Corporate Governance and Compliance · IBIO
-
Authorized Share Increase to 500M
Proposal 4 seeks to increase authorized common shares from 275 million to 500 million, leaving 306.4 million shares authorized but unissued after the increase.
-
Equity Plan Evergreen Amendment
Proposal 5 adds 3% of pre-funded warrants to the annual 5% evergreen increase for 2027-2029, addressing the 93.4 million pre-funded warrants outstanding (approximately 136% of common shares).
-
FY2027 Executive Salary Increases
Base salaries rise to $625,000 for CEO Brenner, $470,000 for CFO Duran, and $445,000 for CLO Banjak, up 8-13% from FY2026.
-
Annual Meeting Set for October 14, 2026
Record date is September 1, 2026; proxy materials mail on or about September 14, 2026.
Analysis · IBIO · Life Sciences
The definitive proxy confirms iBio's plan to increase authorized shares from 275 million to 500 million, creating headroom for future financing. More notably, Proposal 5 amends the equity plan's evergreen provision to include pre-funded warrants in the annual share reserve calculation — a direct response to the 93.4 million pre-funded warrants outstanding, which represent roughly 136% of the current 64.3 million common shares. Without this amendment, the company's equity incentive capacity would continue to erode relative to its true economic capitalization. The filing also discloses FY2027 base salary increases for all named executive officers, signaling continued investment in management retention despite a $33 million net loss in FY2026.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IBIO was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.7M. The 52-week trading range was $0.77 to $3.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.